Donnelly, Douglas
Bajaj, Shirin
Yu, Jaehong
Hsu, Miles
Balar, Arjun
Pavlick, Anna
Weber, Jeffrey
Osman, Iman
Zhong, Judy
Funding for this research was provided by:
National Cancer Institute (P30CA016087)
Article History
Received: 7 March 2019
Accepted: 31 July 2019
First Online: 19 August 2019
Ethics approval and consent to participate
: The patient data used in this manuscript comes from patients that were prospectively enrolled in the NYU Interdisciplinary Melanoma Cooperative Group (IMCG), which has been in existence since 2002. Biospecimens, clinicopathological data, and follow-up information are collected using developed protocols and Standard Operating Procedure (SOP). Upon consent, each patient is assigned a unique identification number. From review of patients’ medical records, trained data managers capture clinical and pathological information in 335 fields in the REDCap database. Physicians in the NYU Departments of Dermatology, Pathology, Surgery, and Oncology, as well as Biostatisticians, were involved in the design of the database and the definitions of the data collection fields. Demographic background, personal and family history of disease, pathological diagnoses, radiological imaging reports, sentinel lymph node mapping, disease staging, treatment, and continuing clinical follow-up information, all compiled from thorough review of medical records and clinician interview, are incorporated into the database. Neither the name nor identifying information for an individual patient is used in program publications.
: Not applicable.
: The authors declare that they have no competing interests.